Colorectal cancer (CRC) remains a major cause of cancer-related deaths in advanced disease, and activating KRAS/NRAS mutations limit the use of anti-EGFR antibodies to RAS-wild-type tumors. This evidence concerns the gene NRAS and colorectal carcinoma.